# Dose Response to Recombinant Factor VIIa When Administered for Bleed

> **NCT00104455** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 64 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Healthy

## Interventions

- **DRUG:** activated recombinant human factor VII

## Key facts

- **NCT ID:** NCT00104455
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2004-11
- **Final completion:** 2004-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2017-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00104455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00104455, "Dose Response to Recombinant Factor VIIa When Administered for Bleed". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00104455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*